NCT07731347 Two Different Therapeutic Interventions Applied During Blood Sampling in Children
| NCT ID | NCT07731347 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Igdir University |
| Condition | Blood Sampling |
| Study Type | INTERVENTIONAL |
| Enrollment | 105 participants |
| Start Date | 2026-08-01 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 105 participants in total. It began in 2026-08-01 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research is a three-group, randomized controlled experimental study designed to determine the effect of two different therapeutic interventions applied during blood sampling on pain, anxiety, and fear levels in children aged 5-7 years. Children participating in the study will be randomly divided into three groups: 1. Group (Experiment 1): Distraction method using betta fish observation 2. Group (Experiment 2): Distraction method using hand puppets 3. Group (Control): Routine clinical practice (without any therapeutic intervention) Before, during, and after blood sampling, children's pain level (FLACC scale), fear level (child fear scale), and anxiety level (child anxiety scale) will be evaluated.
Eligibility Criteria
Inclusion Criteria: * Being between 5 and 7 years old, * Having a scheduled venous blood sampling procedure in the Pediatric Emergency Unit, * Having a level of consciousness suitable for communication, * The child and their parents agreeing to participate in the study, * Being able to communicate in Turkish. Exclusion Criteria: Inability to participate in the application due to visual or hearing problems, * Inability to administer the scales due to a developmental or neurological disease, * Being under the influence of sedative or analgesic medication, * Inability to complete the application during the research process, * Lack of parental consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07731347 clinical trial?
This trial is open to participants of all sexes, aged 5 Years or older, up to 7 Years, studying Blood Sampling. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07731347 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07731347 currently recruiting?
Yes, NCT07731347 is actively recruiting participants. Contact the research team at edagulbetekin@gmail.com for enrollment information.
Where is the NCT07731347 trial being conducted?
This trial is being conducted at Iğdır, Turkey (Türkiye).
Who is sponsoring the NCT07731347 clinical trial?
NCT07731347 is sponsored by Igdir University. The trial plans to enroll 105 participants.